LONDON, June 7 (Reuters) - Boehringer Ingelheim said on Sunday its experimental obesity drug cut visceral and liver fat while minimizing loss of lean mass in ‌a late-stage study, data showed, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results